Navigation Links
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Date:1/27/2009

uick-drying, clear and colorless, fragrance-free hydroalcoholic gel containing oxybutynin chloride, an antispasmodic agent. Applied once daily to the thigh, abdomen, upper arm or shoulder, a one-gram (approx. 1 mL) dose of 100mg/g GELNIQUE delivers a consistent dose of oxybutynin through the skin over a 24-hour period, providing strong efficacy without sacrificing tolerability.

The approval of GELNIQUE is based on a Phase 3 randomized, double-blind, placebo-controlled, parallel group trial that evaluated a total of 789 patients with signs and symptoms of OAB. Over the 12-week trial, a one-gram, once-daily dose of GELNIQUE was superior to placebo at relieving OAB symptoms, including a reduction in incontinence episodes and urinary frequency, and an increase in urine void volume. The treatment was well tolerated in the study with a low incidence of adverse events and no treatment-related serious adverse events. The most frequently reported treatment-related adverse events (>2% and greater than placebo) were dry mouth (6.9%) and application-site reactions (5.4%).

Additional pharmacology studies showed that showering one hour or later, or the application of sunscreen 30 minutes before or after GELNIQUE application did not significantly alter the absorption of the drug.

For full prescribing information, please visit www.gelnique.com.

About OAB

OAB is characterized by a sudden, uncomfortable need to urinate with or without urge incontinence (urine leakage), and usually includes more frequent urination and nocturia (waking up at least once during the night to urinate). It affects as many as 33 million adults in the U.S. - more than diabetes or asthma.

More than an "inconvenience," OAB is disabling and associated with a marked decrease in health-related quality of life as well as higher rates of dep
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
4. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
5. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
6. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
7. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
8. Clexane(R)/Lovenox(R) Approved in Japan
9. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
10. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
11. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 23, 2012 SiREM ( www.siremlab.com ) and ... signing of a Sales Agency Agreement between the ... Tersus Environmental will market, promote and sell SiREM,s ... as well as Gene-Trac® molecular testing services and ...
... Mich. and AMSTERDAM, Feb. 23, 2012   Rubicon ... sample-specific pre-analytical processes to improve the capabilities ... platforms, today announced a clinical supply agreement ... TransPLEX® whole genome RNA amplification technology.  Agendia ...
... Inc. (OTCBB: AMBS), a biotechnology company developing MANF, ... Gerald E. Commissiong, President and CEO, will present ... National Investment Banking Association (NIBA) conference on Thursday, ... Pavillon Hotel in New Orleans, LA. Mr. Commissiong ...
Cached Biology Technology:Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans 2
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... hundred births, Down syndrome - or trisomy 21 - ... It results from a chromosomal abnormality where cells of ... (1% of the human genome). A study conducted by ... Genetic Medicine and Development at the University of Geneva ... shed light on how the extra chromosome 21 upsets ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... PHILADELPHIA People with the heritable disorder of the ... develop basal cell carcinoma of the skin may have ... According to results of a placebo-controlled, randomized, double-blind, Phase ... inhibiting the development of basal cell carcinomas in a ...
... being recognized for devising a new way to study a ... investigating its role in the communication of important genetic messages ... Last year, the team, led by J. Andrew Hockert, at ... Health Science Center School of Medicine, put in its crosshairs ...
... HILL Bacteria can swim, propelling themselves through fluids using ... strolling along solid surfaces using little fibrous legs called pili. ... establish the infections such as meningitis that cause ... Now researchers at the University of North Carolina at Chapel ...
Cached Biology News:Celebrex inhibited the burden of skin cancer in high-risk patients 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 3A single atom controls motility required for bacterial infection 2A single atom controls motility required for bacterial infection 3
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: